Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
about
The Relationship between NALP3 and Autoinflammatory SyndromesPotential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study.A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever.Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for ManagementFamilial Mediterranean fever in childhood: a single-center experience.A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner.Canakinumab for the treatment of familial Mediterranean fever.The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases.Familial Mediterranean fever, review of the literature.The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever.[IL-1-blockade with Anakinra during pregnancy : Retrospective analysis of efficacy and safety in female patients with familial Mediterranean fever].Clinical update on inflammasomopathies.Canakinumab Investigated for Treating Familial Mediterranean Fever.PW01-012 – Canakinumab in patients with FMF.Familial Mediterranean fever mimicking Crohn disease: A case report.Dynamics of Inflammatory Response in Autoinflammatory Disorders: Autonomous and Hyperinflammatory States
P2860
Q26749025-4CA64248-1FC6-4361-845D-EBC865370674Q33710807-C6154987-395E-4C9D-B2D6-CF484D46151AQ36798016-5E176F39-72E0-471B-9DA1-0CE20F6AECA6Q37361075-253560EE-73A2-476E-A27D-7736F52ECCEDQ37708258-03088B47-02C8-4C8C-9363-ABDA1377E749Q37716794-C8402880-28EC-4A28-89CD-C651E18D6EAAQ38614765-1935528A-E824-4A77-8E1A-AB07C1430521Q38773387-C6D2D404-F1CE-4C96-A6EE-98F081CFED27Q38865019-27858B20-0830-41C2-81E0-203C5EC996C0Q39132605-286A00FF-F59A-4A8B-9181-57009257C76DQ39380468-A75EE3EA-AB54-4873-B4A2-545104697F4BQ39426709-CF3FB11B-7787-4ACA-8530-9DF458FB1E00Q40045757-00E3CF13-2823-4C02-8447-B01D16AC1500Q40062051-A6D7B596-7BD4-451F-9253-A3E71DFD89C0Q40089782-194A2369-5121-4E82-A44C-A5210C396A62Q46053276-E1FD0723-9CA3-4156-983B-E399EC38942CQ52728876-5D7BCF4A-9F59-4E46-9ED7-EDCB5AC4FB7FQ58606312-6B6A6651-9474-4058-ABEB-4758ABF9B54A
P2860
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Efficacy and safety of canakin ...... t familial Mediterranean fever
@ast
Efficacy and safety of canakin ...... t familial Mediterranean fever
@en
type
label
Efficacy and safety of canakin ...... t familial Mediterranean fever
@ast
Efficacy and safety of canakin ...... t familial Mediterranean fever
@en
prefLabel
Efficacy and safety of canakin ...... t familial Mediterranean fever
@ast
Efficacy and safety of canakin ...... t familial Mediterranean fever
@en
P2093
P2860
P1476
Efficacy and safety of canakin ...... t familial Mediterranean fever
@en
P2093
Burak Erer
Huri Ozdogan
Nicole Davis
Serdal Ugurlu
Serhan Sevgi
P2860
P2888
P356
10.1186/S13075-015-0765-4
P577
2015-09-04T00:00:00Z